Corporate PresentationJAN 2018

1

• Private VC-backed company based in

Belgium

• Targeting Glaucoma, a major market with

high potential for growth

• Lead product MINIject™ completed

enrolment of First-In-Human clinical trial

• Exclusive rights to

innovative anti-fibrotic

STAR® material

Developing a

new generation

of MIGS made of

anti-fibrotic

material

2

iSTAR Key Messages

MINIject™ STAR® material

History of iSTAR Medical

3

2011STARflo

(Ab externo GDD)

First In Human

2013Series A financing

€4 Mln

2014STARflo

First multicentre

clinical trial

2016Series B financing

€10 Mln

2010iStar Medical founded

2016MINIject (MIGS)

Design finalised

2017MINIject

First In Human

2011Grants from

Belgium

Region

Scientific & Clinical Advisors

4

Andrew Marshall, Ph.D.

Chief Technology Officer

Healionics, Seattle, USA

Christophe Baudouin, MD, Ph.D.

Chairman, Department of

Ophthalmology, Hopital des Quinze-

Vingt, Paris, France

Steven Vold, MD

Assistant Professor, Department

of Ophthalmology & Surgery

Fayetteville, Arkansas, USA

Murray Johnstone, MD

Professor of Ophthalmology,

University of Washington,

Seattle, USA

Ike Ahmed, MD

Assistant Professor at the

University of Toronto, Canada

Norbert Pfeiffer, MD, Ph.D.

Director of Dpt of Ophthalmology,

University Medical Center of Mainz,

Germany

Philippe Denis, MD, Ph.D.

Head Ophthalmology Department,

Croix-Rousse University Hospital,

Lyon, France

Julian Garcia Feijoo, MD, Ph.D.

Professor and Chairman of

Opthalmology at Universidad

Complutense, Madrid, Spain

Board of Directors and Management Team

Philippe Degive

• Representative of Société Régionale d'Investissement de Wallonie (“SRIW”)

• Current and past board memberships: one Therapeutics, Promethera

Biosciences, Ogeda, Cardio Life Research

David Guyer, MD

• Co-Founder & Chairman of Ophthotech Corp.

• Previously: SV Life Sciences. Co-founder of Eyetech Pharmaceuticals, Inc.,

• B.S. from Yale College & M.D. from Johns Hopkins

Max Maginness

• President and co-founder, Healionics Corporation

• Formerly with Siemens Medical, ATL (now Philips Ultrasound) and

subsidiaries of CIBA-Geigy managing multiple new product development

and technology transfer projects

Marc Nolet de Brauwere

• CEO of PhysIOL (cutting-edge IOLs)

• Current board membership: Bone Therapeutics, Cardiatis, Mymicroinvest,

Endo Tools Therapeutics, Biotech Coaching and Aliaxis

Katya Smirnyagina

• Partner, Capricorn Health-Tech Venture Fund

• Formerly with Alta Partners

• Current and past board memberships: Adocia, Confo Therapeutics,

Nexstim, Ablynx, Cerenis Therapeutics, Innate Pharma and Kiadis Pharma

Marty Wax, MD

• CMO and Executive VP of R&D at PanOptica, Inc.

• Formerly VP and Head of Discovery Research and Pre-Clinical Sciences at

Alcon

• Clinical Professor of Ophthalmology and Visual Sciences at Rutgers

Medical School in Newark, N.J.

Michel Vanbrabant, CEO

• 20+ years of experience in Medical Technology

• Held several international positions at leading MedTech companies

including Guidant Inc. (now Boston Scientific) and St.Jude Medical

• Experience in several start-up organisations with a focus on go-to

market strategy and implementation

Zubair Hussain, Regulatory & Clinical Affairs

• 20+ years experience in Regulatory, Quality, Compliance and Clinical

Affairs for Pharmaceutical and Medical Device companies including in

Vision care

• Formerly with Pfizer, Alcon, Ipsen

Dan Scherrer, Operations

• 20+ years experience in Operations, Product Development and Supply

Chain Management for Medical Device, Food and Electronics.

• Formerly with DePuy Spine (JNJ), Synthes, Biwi

Cecile Roy, Manufacturing

• 7 years of research experience with bio-polymeric products for drug

delivery applications

• Co-inventor of the MINIject device

5

Bo

ard

of

Dir

ect

ors

Man

ag

em

en

t Team

Michel Lussier, Chairman of the Board• CEO of Metronom Health, Chairman of Celyad

• Formerly a senior executive with Medtronic and Volcano

Ch

air

man

CEO

Associated with elevated Intraocular Pressure

(IOP) in most cases

Proven therapeutic options aim at lowering

IOP

Progressive, sight-

threatening disease,

largely asymptomatic

Second cause of

blindness after macular

degeneration

worldwide22

6

Glaucoma

Sources:

1. Market Scope estimates for Glaucoma prevalence (September 2016)

2. WHO/NMH/PBD/12.01 – Global data on visual impairments 2010 & Glaucoma Devices: Progress On

Multiple Fronts, Elsevier Business Intelligence, April 2013

>80 million

people

>90 million

people 1

2016 2021

Blocked drainage

canal builds up

fluid

Excess fluid increases

pressure which

damages optic nerve

The STAR® anti-fibrotic material

7

• Medical grade silicone with precision-pore geometry

• Soft, flexible, tissue-friendly

Developed at the University of Washington, Seattle, USA

iSTAR has exclusive IP rights in Ophthalmology to the STAR® anti-fibrotic material

Pore Throat

The STAR® anti-fibrotic material

Rabbit Study, Suprachoroidal Placement – 6m Follow Up

8

IrisCornea

Sclera

Choroid

STARflo

Retina

No Encapsulation

observed as shown by the

absence of a continuous

surrounding fibrous

capsule, nor continuous

macrophage, nor a

continuous fibroblast layer

Exceptional

Biointegration

of the device with

surrounding tissue

colonizing the porous

structure while preserving

in vivo drainage efficacy

Source:

Prof. Nathalie Collignon (CHU of Liège, Liège, Belgium); In-

vivo: CER Groupe (Marloie, Belgium); Histology: GIGA-ULg

Immunohistology Platform (University of Liège, Liège,

Belgium). March 2013.

iSTAR Product Pipeline

9

Feasibility study complete

Multi-center Study in

progress

>100 patients implanted

First-in-Human Study in

progress

CE-marking Study

planned H2-2018

STARflo

MINIject

STAR ®

anti-fibrotic material Ab Externo

Implant

MIGS

Served as a proof of concept for the STAR material

COMMERCIAL PRODUCT

• Micro-invasive technology which is safe and

easy to implant in a single-step procedure

• Entirely made of proprietary anti-fibrotic

STAR material

• Designed for significant and sustained IOP

reduction

• Targeting the supra-choroidal space - no

bleb formation

• Strong IP around material, device design

and implantation method

• Developed in close collaboration with world

leading KOLs – understanding real patient

needs

The next

generation MIGS

made of

anti-fibrotic

STAR material

10

MINIject

MINIject™

The MINIject™ Glaucoma Drainage System

11

• Ergonomic shape

for optimal grip

and precision

Handle Shaft

• Pre-loaded with implant

• Smooth pull-back release

mechanism

• Delivery through a small

corneal incision of

2.0mm.

• Can be performed by

cataract and glaucoma

surgeons.

Targeting the suprachoroidal space - Avoiding bleb formation

Company Milestones

12

H1-2018STARflo

Results from

Multi-centre

clinical trial

2016Series B financing

€10 Mln

H2-2018MINIject

IDE Filing

H1-2017MINIject

First Patient

in FIH Study

✓

✓

H1-2018Next financing round

H2-2019MINIject

CE mark